Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Short Interest Update

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 758,697 shares, a growth of ∞ from the April 30th total of 0 shares. Approximately 1.7% of the company’s shares are short sold. Based on an average daily volume of 622,622 shares, the short-interest ratio is currently 1.2 days.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on COAG. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price objective on the stock. Wedbush began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 price objective on the stock. Finally, The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.75.

Hemab Therapeutics Trading Down 4.8%

Shares of NASDAQ:COAG traded down $1.37 on Monday, reaching $27.13. The company had a trading volume of 128,154 shares, compared to its average volume of 223,243. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. acquired 3,802 shares of the stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average cost of $24.97 per share, with a total value of $94,935.94. Following the purchase, the insider directly owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. This trade represents a 0.06% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders purchased 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.